Esplenectomía y aumento subsiguiente del riesgo de cáncer

1. R.E. Mebius, G. Kraal. Structure and function of the spleen. Nat Rev Immunol, 5 (2005), pp. 606–616
2. A. Wluka, W.L. Olszewski. Innate and adaptive processes in the spleen. Ann Transplant, 11 (2006), pp. 22–29
3. I. Davies, J. Cho, M. Lewis. Splenectomy results from an 18-year single centre experience. Ann R Coll Surg Engl, 96 (2014), pp. 147–150
4. K.A. Bickenbach, M. Gonen, D.M. Labow, et al. Indications for and efficacy of splenectomy for haematological disorders. Br J Surg, 100 (2013), pp. 794–800
5. J.W. Hadden. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol, 3 (2003), pp. 1061–1071
6. K. Salavoura, A. Kolialexi, G. Tsangaris, et al. Development of cancer in patients with primary immunodeficiencies. Anticancer Res, 28 (2008), pp. 1263–1269
7. R.W. Chang, J.L. Turk. Increased resistance in splenectomized mice to a methylcholanthrene-induced tumour. Br J Cancer, 35 (1977), pp. 768–776
8. R.T. Prehn. The paradoxical effects of splenectomy on tumor growth. Theor Biol Med Model, 3 (2006), p. 23
9. G. Kossoy, H. Ben-Hur, O. Lifschitz, et al. Mammary tumors in splenectomized rats. Oncol Rep, 9 (2002), pp. 185–188
10. H. Ben-Hur, G. Kossoy, O. Lifschitz, et al. Splenectomy, chemically-induced mammary tumors and parathymic lymph nodes in rats: experimental and morphological studies. In Vivo, 16 (2002), pp. 275–280
11. K. Sonoda, K. Izumi, Y. Matsui, et al. Decreased growth rate of lung metastatic lesions after splenectomy in mice. Eur Surg Res, 38 (2006), pp. 469–475
12. J. Higashijima, M. Shimada, M. Chikakiyo, et al. Effect of splenectomy on antitumor immune system in mice. Anticancer Res, 29 (2009), pp. 385–393
13. S.Y. Kristinsson, G. Gridley, R.N. Hoover, et al. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica, 99 (2014), pp. 392–398
14. M.S. Linet, O. Nyrén, G. Gridley, et al. Risk of cancer following splenectomy. Int J Cancer, 66 (1996), pp. 611–616
15. L. Mellemkjoer, J.H. Oslen, M.S. Linet, et al. Cancer risk after splenectomy. Cancer, 75 (1995), pp. 577–583
16. C.J. Chiang, Y.C. Chen, C.J. Chen, et al. Taiwan Cancer Registry Task Force. Cancer trends in Taiwan. Jpn J Clin Oncol, 40 (2010), pp. 897–904
17. Cancer Statistics Annual Report. Taiwan Cancer Registry. Available at: http://tcr.cph.ntu.edu.tw/main.php?Page=N2. Accessed October 2, 2014.
18. B.K. Edwards, A.M. Noone, A.B. Mariotto, et al.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cáncer. Cancer, 120 (2014), pp. 1290–1314
19. Cancer Prevention. World Health Organization. Available at: http://www.who.int.elibrary.einstein.yu.edu/cancer/prevention/en/. Accessed October 2, 2014.
20. C.H. Kao, L.M. Sun, P.C. Chen, et al.  A population-based cohort study in Taiwan—use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol, 24 (2013), pp. 523–530
21. M. Altamura, L. Caradonna, L. Amati, et al. Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial clearance. Immunopharmacol Immunotoxicol, 23 (2001), pp. 153–161
22. H. Coignard-Biehler, F. Lanternier, M. de Montalembert, et al. [Infections in splenectomized patient]. Rev Prat, 58 (2008), pp. 2209–2214
23. J.M. Glass, J.M. Gilbert. Splenectomy in a general hospital. J R Soc Med, 89 (1996), pp. 199–201
24. J.C. de Beer, L. Liebenberg. Does cancer risk increase with HbA1c, independent of diabetes?
25. A.L. Ronco, E. De Stefani, H. Deneo-Pellegrini, et al. Diabetes, overweight and risk of postmenopausal breast cancer: a case-control study in Uruguay. Asian Pac J Cancer Prev, 13 (2012), pp. 139–146
26. W.H. Chow, G. Gridley, J.F. Fraumeni Jr., et al. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med, 343 (2000), pp. 1305–1311
27. J.A. Kaye, C.R. Meier, A.M. Walker, et al. Statin use, hyperlipidaemia, and the risk of breast cáncer Br J Cancer, 86 (2002), pp. 1436–1439
28. I.I. Herbey, N.V. Ivankova, V.R. Katkoori, et al. Colorectal cancer and hypercholesterolemia: review of current research. Exp Oncol, 27 (2005), pp. 166–178
29. K. Pelton, M.R. Freeman, K.R. Solomon. Cholesterol and prostate cáncer. Curr Opin Pharmacol, 12 (2012), pp. 751–759
30. L.M. Sun, M. Epplein, C.I. Li, et al. Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol, 162 (2005), pp. 1174–1178
31. C.C. Hull, P. Galloway, N. Gordon, et al. Splenectomy and the induction of murine colon cáncer. Arch Surg, 123 (1988), pp. 462–464
32. A. Lamb, L.F. Chen. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cáncer. J Cell Biochem, 114 (2013), pp. 491–497
33. C.D. Robinette, J.F. Fraumeni Jr. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet, 2 (1977), pp. 127–129
34. G. Bertolino, P. Noris, C.L. Balduini. Qualitative and quantitative platelet defect with bleeding symptoms as presenting feature of non-Hodgkin’s lymphomas. Haematologica, 76 (1991), pp. 243–244
35. J.F. Kirshner, K.W. Zamkoff, A.J. Gottlieb. Idiopathic thrombocytopenic purpura and Hodgkin’s disease: report of two cases and a review of the literatura. Am J Med Sci, 280 (1980), pp. 21–28
36. N. Sato, M.C. Michaelides, M.K. Wallack. Effect of splenectomy on the growth of murine colon tumors. J Surg Oncol, 22 (1983), pp. 73–76
37. S. Kopel, M. Michowitz, J. Leibovici. Effect of splenectomy on the efficiency of chemo-immunotherapy of melanoma-bearing mice. Int J Immunopharmacol, 7 (1985), pp. 801–810
38. H. Yamagishi, T. Oka, I. Hashimoto, et al. The role of the spleen in tumor bearing host: II. The influence of splenectomy in mice. Jpn J Surg, 14 (1984), pp. 72–77
39. S. Schwarz, H. Messerschmidt, M. Doren. Psychosocial risk factors for cancer development. Med Klin (Munich), 102 (2007), pp. 967–979